ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Virginia's MULTIDISCIPLINARY CANCER CARE TEAMs and the PATIENTS THEY SERVE since 1990
Meetings & Education
State Society Education Series
VAHO Advocacy Support
Patient Advocacy Organizations
State & Federal Resources
Find A Clinical Trial
Off-Label Use Literature
National Professional organizations
Financial Advocacy & Patient Assistance
VAHO Corporate Members
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
CMS Assigns New J-Codes for Rituxan and Rituxan Hycela
Effective January 1, 2019, the Centers for Medicare & Medicaid Services (CMS) has assigned new J-codes for Rituxan and Rituxan Hycela (Genentech, Inc.):
Injection, rituximab, 10 mg (replaces J-code J9310)
Injection, rituximab 10 mg and hyaluronidase
These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements.
Read more about the new J-codes for Rituxan and Rituxan Hycela here.